At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
PCRX Pacira Pharmaceuticals
Market Closed 06-28 16:00:00 EDT
28.61
+0.70
+2.51%
盘后28.61
+0.000.00%
17:21 EDT
High28.95
Low27.89
Vol2.33M
Open28.15
D1 Closing27.91
Amplitude3.80%
Mkt Cap1.33B
Tradable Cap1.32B
Total Shares46.55M
T/O66.68M
T/O Rate5.07%
Tradable Shares46.06M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Declining Stock and Decent Financials: Is The Market Wrong About Pacira BioSciences, Inc. (NASDAQ:PCRX)?
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.